Clinical trials: Immunocompromised Host
Influenza, Human
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
This 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the…
- Trial name
- NCT00545532
- Testing
- oseltamivir
- Where
- 208 sites in United States, Argentina and 24 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Fungal Infection
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.
- Trial name
- NCT00292071
- Testing
- caspofungin acetate
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (<) 13 years of age, with confirmed…
- Trial name
- NCT01715909
- Testing
- Oseltamivir
- Where
- 50 sites in United States, Belgium and 13 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Parainfluenza
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
- Trial name
- PIV (NCT01924793)
- Testing
- DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
- Where
- 23 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ansun Biopharma, Inc.
Infection, Infections, Bacterial
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection…
- Conditions
- Infection, Infections, Bacterial, Infections, Fungal, Infection Viral
- Trial name
- OPTIMUM (NCT07110636)
- Testing
- Metagenomic plasma-based test for agnostic pathogen detection
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Karius, Inc.
Chikungunya Virus Infection
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
This was a phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of VLA1553 in moderately immunocompromised adults with HIV infection.
- Trial name
- NCT06028841
- Testing
- VLA1553
- Sponsor
- Valneva Austria GmbH
Fever, Cancer
Remote Temperature Monitoring of Patients At Risk for Developing Fever
The purpose of this program is to evaluate remote temperature monitoring in cancer patients at risk of fever and infection due to chemotherapy treatment.
- Conditions
- Fever, Cancer, Remote Patient Monitoring
- Trial name
- NCT06752512
- Testing
- Remote Patient Monitoring
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- AION Biosystems
COVID-19 Infection
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone…
- Trial name
- NCT07013474
- Testing
- ibuzatrelvir, remdesivir
- Where
- 159 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
Candidiasis, Esophageal, HIV Infections
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
- Trial name
- NCT00002041
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Rabies Exposure, Immunocompromised
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients…
- Conditions
- Rabies Exposure, Immunocompromised, Chronic Disease
- Trial name
- NCT07120464
- Testing
- Observation Only
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
EBV Viremia
Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients
The NeuMoDx EBV Quant Assay 2.0 study is a multi-center, observational clinical investigation designed to evaluate the performance of the NeuMoDx EBV Quant Assay 2.0 in quantifying Epstein-Barr virus (EBV) DNA levels in plasma…
- Trial name
- NCT06681025
- Testing
- NeuMoDx EBV Quant 2.0 Assay
- Where
- United Kingdom
- Volunteers
- 1,070 people
- Sponsor
- QIAGEN Gaithersburg, Inc
COVID-19, SARS-CoV-2
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.
- Trial name
- VICTORIA (NCT05057897)
- Testing
- AZD1222
- Where
- 4 sites in Thailand, Ukraine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV Infections
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.
- Trial name
- NCT00002308
- Testing
- Stavudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Pneumonia, Bacterial, Pneumonia, Viral
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Given the need for a more sensitive pathogen detection test in patients with immunocompromised pneumonia, this study will evaluate the performance of the Karius Test, a novel NGS blood test for the diagnosis of infectious…
- Conditions
- Pneumonia, Bacterial, Pneumonia, Viral, Pneumonia Fungal, Pneumonia Cavitary
- Trial name
- PICKUP (NCT04047719)
- Testing
- Karius Test
- Where
- 10 sites in United States
- Volunteers
- 257 people
- Sponsor
- Karius, Inc.
Cancer
Safety Study to Evaluate FluMist in Immunocompromised Children
The main purpose of this study is to get information about the safety of a flu vaccine spray, called FluMist, in children with cancer.
- Trial name
- NCT00112112
- Testing
- FluMist
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- MedImmune LLC
Herpes Simplex, HIV Infections
The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment
PRIMARY: To evaluate the clinical activity of foscarnet cream on the index lesion of mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients previously unresponsive to acyclovir treatment.
- Trial name
- NCT00002144
- Testing
- Foscarnet sodium
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Astra USA
Respiratory Syncytial Virus Infection
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.
- Trial name
- NCT01466062
- Testing
- Palivizumab
- Where
- 6 sites in Japan
- Volunteers
- 28 people
- Sponsor
- AbbVie (prior sponsor, Abbott)